The US Department of Defense just made life significantly harder for one of the world’s largest pharmaceutical contract manufacturers. WuXi AppTec, the Shanghai-based firm that helps develop and produce drugs for a huge swath of the global pharma industry, has been added to the Pentagon’s list of companies with alleged ties to the Chinese military.
The June 2026 update to the Section 1260H list, which identifies Chinese military companies operating in the United States, brings the total number of designated entities to 188. WuXi AppTec joins a fresh batch of additions that also includes Alibaba, Baidu, BYD, RoboSense, and Unitree. The company, which employs approximately 1,900 people across eight US states, says the designation is wrong and plans to fight it.
What the designation actually does
Being named doesn’t automatically freeze assets or ban transactions. What it does is restrict the Department of Defense from procuring goods and services from these companies, and it sends a signal to every other US government agency and private contractor that doing business with the listed entity carries risk.
The DoD cited WuXi AppTec’s alleged indirect ownership by China’s State-Owned Assets Supervision and Administration Commission, known as SASAC, along with affiliations with military-related entities. WuXi has pushed back forcefully, pointing to its US-based operations, local job creation, and community investments as evidence that the designation mischaracterizes the company’s role and purpose.
